AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30577725 — intervention group
Group type: EXPERIMENTAL
Intervention: Group handwashing station
Number of subjects: 95
Study 30514048 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified incision group
Number of subjects: 40
Study 30514048 — intervention group
Group type: COMPARATOR
Intervention: Routine incision group
Number of subjects: 40
Study 30514048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26772193 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy
Number of subjects: 37
Study 26772193 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (in patients not receiving antibiotics)
Number of subjects: 37
Study 24982917 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/ml levobupivacaine plus 2 mcg/ml fentanyl
Number of subjects: 80
Study 24982917 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/ml levobupivacaine
Number of subjects: 80
Study 22905886 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (EM) on post-operative day 2
Number of subjects: 50
Study 22905886 — intervention group
Group type: COMPARATOR
Intervention: Late mobilization (LM) on post-operative day 7
Number of subjects: 50
Study 22905886 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (EM)
Number of subjects: 50
Study 22905886 — intervention group
Group type: COMPARATOR
Intervention: Late mobilization (LM)
Number of subjects: 50
Study 20457157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral viscous budesonide (OVB) 1 mg for patients <5 feet tall and 2 mg for patients >=5 feet tall, daily for 3 months
Number of subjects: 24
Study 20457157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18509786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (n = 22)
Number of subjects: 46
Study 18509786 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (n = 24)
Number of subjects: 46
Study 18509786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological closure (NSAIDs treatment)
Number of subjects: 46
Study 18509786 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed pharmacological closure
Number of subjects: 46
Study 16202594 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme using cartoons, video-recording, print materials, and face-to-face educational methods
Number of subjects: 1131
Study 16202594 — intervention group
Group type: COMPARATOR
Intervention: 2 hour lecture about schistosomiasis
Number of subjects: 1131
Study 11897647 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil
Number of subjects: 470
Study 11897647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study 9609358 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological mixed meal ingestion in Type 2 DM patients
Number of subjects: 14
Study 9609358 — intervention group
Group type: COMPARATOR
Intervention: Physiological mixed meal ingestion in non-diabetic controls
Number of subjects: 14
Study 9609358 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 DM patients
Number of subjects: 14
Study 7891492 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomised controlled trials
Number of subjects: 185
Study 7891492 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis demonstrating a protective effect from an intervention of more than 40%
Number of subjects: 185
Study 2797920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized aerosol (2 mg terbutaline)
Number of subjects: 13
Study 2797920 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (2 mg terbutaline)
Number of subjects: 13
Study 2797920 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler (1 mg terbutaline)
Number of subjects: 13
Study 507256 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of bivalent split virus vaccine (A/New Jersey/76 and A/Victoria/75) intradermally
Number of subjects: 2
Study 507256 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml of bivalent split virus vaccine (A/New Jersey/76 and A/Victoria/75) subcutaneously
Number of subjects: 2
Study 31586596 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion strategy
Number of subjects: 60
Study 31586596 — intervention group
Group type: COMPARATOR
Intervention: Self-critical rumination
Number of subjects: 60
Study 30297351 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine protein hydrolysate (MPH) 3 g per day for 12 months
Number of subjects: 100
Study 30297351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27267603 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy-appropriate 'dirty bomb' decision aid
Number of subjects: 50
Study 27267603 — intervention group
Group type: COMPARATOR
Intervention: CDC 'factsheet' (control)
Number of subjects: 50
Study 25275318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory plasma markers and monocyte subsets in TB-IRIS patients pre-ART and at the time of IRIS
Number of subjects: 0
Study 25275318 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14(++)CD16(-) monocytes frequency
Number of subjects: 0
Study 25275318 — intervention group
Group type: EXPERIMENTAL
Intervention: Production of inflammatory cytokines by monocytes
Number of subjects: 0
Study 25275318 — intervention group
Group type: COMPARATOR
Intervention: Pro-inflammatory biomarkers
Number of subjects: 0
Study 21835513 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based peer review tool
Number of subjects: 20
Study 21835513 — intervention group
Group type: COMPARATOR
Intervention: Paper-based peer review tool
Number of subjects: 20
Study 21835513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tools
Number of subjects: 20
Study 20682320 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1 mg twice daily for 15 days)
Number of subjects: 0
Study 20682320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17978591 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 to 25 mg bid
Number of subjects: 1235
Study 17978591 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 50 to 200 mg bid
Number of subjects: 1235
Study 17978591 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1235
Study 17978591 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1235
Study 17978591 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol and Metoprolol
Number of subjects: 1235
Study 17978591 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol vs Metoprolol
Number of subjects: 1235
Study 15545661 — intervention group
Group type: COMPARATOR
Intervention: AC (adjuvant doxorubicin/cyclophosphamide)
Number of subjects: 0
Study 15545661 — intervention group
Group type: EXPERIMENTAL
Intervention: AC+T (adjuvant doxorubicin/cyclophosphamide followed by paclitaxel)
Number of subjects: 0
Study 11933177 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy (CT + RT)
Number of subjects: 210
Study 11933177 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 210
Study 9627359 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (I)
Number of subjects: 20
Study 9627359 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (SU)
Number of subjects: 20
Study 8150016 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-titre Edmonston-Zagreb (EZ) measles vaccine (10(4.6) p.f.u.)
Number of subjects: 75
Study 8150016 — intervention group
Group type: COMPARATOR
Intervention: Standard Schwarz (SW) measles vaccine
Number of subjects: 75
Study 2963054 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 2963054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30940047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful music listening
Number of subjects: 72
Study 30940047 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 72
Study 30940047 — intervention group
Group type: COMPARATOR
Intervention: Audiobook listening
Number of subjects: 72
Study 29992584 — intervention group
Group type: EXPERIMENTAL
Intervention: rs12979860 TT genotype among HIV+ PWID
Number of subjects: 345
Study 29992584 — intervention group
Group type: EXPERIMENTAL
Intervention: rs12979860 TT genotype
Number of subjects: 345
Study 29992584 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of intravenous drug use (IVDU)
Number of subjects: 345
Study 26848570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26848570 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (700 mg)
Number of subjects: 50
Study 26848570 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins E + C (235 mg + 1 g)
Number of subjects: 50
Study 26472571 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction group (ERG) following an energy-restricted diet of -3347.2 kJ/d (-800 kcal/d)
Number of subjects: 21
Study 26472571 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) advised not to change their food intake
Number of subjects: 21
Study 22078985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 20
Study 22078985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 20
Study 22078985 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 22042277 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase (2500 IU/m/dose intramuscularly on days 1 and 15)
Number of subjects: 76
Study 22042277 — intervention group
Group type: COMPARATOR
Intervention: Native E. coli asparaginase (10,000 IU/m/dose intramuscularly on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26)
Number of subjects: 76
Study 22042277 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase
Number of subjects: 76
Study 18628693 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with postural biofeedback
Number of subjects: 47
Study 18628693 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 47
Study 16409194 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen tablets (75,000 SQ‐T)
Number of subjects: 114
Study 16409194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 14531956 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs), specific types and dosages not mentioned, focus on effective treatment for RA.
Number of subjects: 0
Study 14531956 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11028795 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised outpatient-group training programme, 50 min three times a week for 3 months
Number of subjects: 43
Study 11028795 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 9201809 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 28
Study 9201809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7997902 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 0.5 mg/kg
Number of subjects: 32
Study 7997902 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 0.2 mg/kg
Number of subjects: 32
Study 7997902 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 32
Study 3395401 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadocaine hydrochloride 15 mg
Number of subjects: 6
Study 3395401 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadocaine hydrochloride (5, 10, 15, 20, 30, 50 mg)
Number of subjects: 6
Study 31869817 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR® FAB 6-treatment protocol
Number of subjects: 24
Study 31869817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 30761498 — intervention group
Group type: EXPERIMENTAL
Intervention: Contaminated group (exposed to BTEX)
Number of subjects: 0
Study 30761498 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to BTEX)
Number of subjects: 0
Study 29117576 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Müllerian hormone (AMH) assay
Number of subjects: 73
Study 29117576 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH measured at end of chemotherapy
Number of subjects: 73
Study 29117576 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH)
Number of subjects: 73
Study 24626819 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d of algal docosahexaenoic acid (DHA)
Number of subjects: 869
Study 24626819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 869
Study 22656403 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultations from pharmacists regarding asthma self-management over a 3-month period
Number of subjects: 98
Study 22656403 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 98
Study 20149235 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 552
Study 17433955 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐mm catheter (8MC)
Number of subjects: 180
Study 17433955 — intervention group
Group type: EXPERIMENTAL
Intervention: OIC‐1 (open irrigation catheter with higher peak power 50 W)
Number of subjects: 180
Study 17433955 — intervention group
Group type: COMPARATOR
Intervention: OIC‐2 (open irrigation catheter with lower peak power 35 W)
Number of subjects: 180
Study 17433955 — intervention group
Group type: EXPERIMENTAL
Intervention: OIC‐1
Number of subjects: 180
Study 17433955 — intervention group
Group type: COMPARATOR
Intervention: OIC‐2
Number of subjects: 180
Study 17433955 — intervention group
Group type: COMPARATOR
Intervention: 8MC
Number of subjects: 180
Study 16115731 — intervention group
Group type: EXPERIMENTAL
Intervention: LRRK 2 G 2019 S and I 2020 T mutations evaluation in PD patients
Number of subjects: 174
Study 16115731 — intervention group
Group type: COMPARATOR
Intervention: LRRK 2 G 2019 S and I 2020 T mutations evaluation in healthy controls
Number of subjects: 174
Study 12106929 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion at increasing doses in the infarct-related artery (IRA)
Number of subjects: 16
Study 12106929 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion in the IRA after one year
Number of subjects: 16
Study 12106929 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with coronary atherosclerosis)
Number of subjects: 16
Study 10442370 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT plus oral calcium folinate combined with epirubicin and cyclophosphamide
Number of subjects: 0
Study 10442370 — intervention group
Group type: COMPARATOR
Intervention: Continuous-infusion 5-fluorouracil (5-FU)
Number of subjects: 0
Study 7926495 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily)
Number of subjects: 366
Study 7926495 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 366
Study 2555105 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative surgery
Number of subjects: 38
Study 2555105 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative surgery supplemented with physical training
Number of subjects: 38
Study 2555105 — intervention group
Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 38
Study 50828 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement contingency management system
Number of subjects: 10
Study 50828 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent services (Control)
Number of subjects: 10
Study 31562875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained stretch and paraffin
Number of subjects: 23
Study 31562875 — intervention group
Group type: COMPARATOR
Intervention: Sustained stretch only
Number of subjects: 23
Study 29779399 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 28
Study 29779399 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 28
Study 28139240 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer
Number of subjects: 179
Study 28139240 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 179
Study 25647628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib administered at 1 p.m.
Number of subjects: 12
Study 25647628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib administered at 6 p.m.
Number of subjects: 12
Study 25647628 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib administered at 8 a.m.
Number of subjects: 12
Study 25647628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib administered at 4 a.m. and 4 p.m.
Number of subjects: 12
Study 25647628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib administered at different times (8 a.m., 1 p.m., 6 p.m.).
Number of subjects: 12
Study 24369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant (150 mg IV on day 1)
Number of subjects: 372
Study 24369195 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant (125 mg on day 1, 80 mg on days 2 and 3)
Number of subjects: 372
Study 24369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Number of subjects: 372
Study 24369195 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant
Number of subjects: 372
Study 24369195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant and Aprepitant
Number of subjects: 372
Study 21339093 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 35
Study 21339093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 35
Study 18989715 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adjustment of mandibular advancement splint (MAS) for 6 weeks (n = 16)
Number of subjects: 28
Study 18989715 — intervention group
Group type: COMPARATOR
Intervention: Objective adjustment of MAS (fixed position for 3 weeks, then PSG feedback for 3 weeks, n = 12)
Number of subjects: 28
Study 17052970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extract group (botanical extract-based weight loss formula)
Number of subjects: 105
Study 17052970 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 105
Study 12765889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (i.t.) clonidine 150 microg
Number of subjects: 24
Study 12765889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (i.t.) clonidine 50 microg
Number of subjects: 24
Study 12765889 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal (i.t.) bupivacaine with clonidine (150 microg)
Number of subjects: 24
Study 12765889 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) clonidine 150 microg
Number of subjects: 24
Study 10694109 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) 20 g x d(‐1) x 5 d
Number of subjects: 30
Study 10694109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study 10169635 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 10169635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8238193 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (0.05 mg/day)
Number of subjects: 36
Study 8238193 — intervention group
Group type: EXPERIMENTAL
Intervention: Three estradiol implants
Number of subjects: 36
Study 8238193 — intervention group
Group type: EXPERIMENTAL
Intervention: One estradiol implant
Number of subjects: 36
Study 3567018 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg) in young volunteers
Number of subjects: 11
Study 3567018 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (400 mg) in elderly volunteers
Number of subjects: 11
Study 29856114 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dosing for both protein and carbohydrate
Number of subjects: 16
Study 29856114 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate alone
Number of subjects: 16
Study 27012370 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 100
Study 27012370 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway‐Unique
Number of subjects: 100
Study 24752448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (BCG and electromotive mitomycin)
Number of subjects: 0
Study 24752448 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 0
Study 24752448 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy vs BCG alone
Number of subjects: 0
Study 22585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg under fasting conditions
Number of subjects: 49
Study 22585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg under high-fat meal (HFM) conditions
Number of subjects: 49
Study 22585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg under Japanese standard meal conditions
Number of subjects: 49
Study 22585285 — intervention group
Group type: COMPARATOR
Intervention: Control group (fasted state)
Number of subjects: 49
Study 20876412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 600 mg/d over 6 weeks)
Number of subjects: 324
Study 20876412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 20876412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 324
Study 19027496 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer for primary angioplasty
Number of subjects: 5741
Study 19027496 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 5741
Study 15764724 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (3,000 microg/hour) administered through a metered‐dose inhaler and spacer at 10‐minute intervals for 3 hours
Number of subjects: 106
Study 15764724 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydrocortisone (500 mg)
Number of subjects: 106
Study 12426672 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy electron irradiation
Number of subjects: 207
Study 12426672 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-14.25 Gy HDR BT
Number of subjects: 207